Introduction
Ischemic heart disease, particularly coronary heart disease, is a leading cause of morbidity and mortality worldwide. 1 Timely restoration of the coronary blood flow using either thrombolytic therapy or percutaneous coronary intervention is the most effective means of reducing myocardial infarct size and improving the clinical outcome. 2 However, myocardial reperfusion paradoxically induces further myocardial injury, i.e. ischemia-reperfusion (I/R) injury. 3, 4 Several mechanisms including oxidative stress, intracellular Ca 2þ overload, opening of the mitochondrial permeability transition pore, and inflammation have been implicated in I/R injury. [5] [6] [7] [8] [9] Previous studies have demonstrated two major intrinsic signalling pathways that protect the heart from I/R injury: the reperfusion injury salvage kinase (RISK) pathway (consisting of the PI3K-Akt-GSK3b axis and the ERK1/2 signalling cascade), 10 and the survivor activating factor enhancement (SAFE) pathway (namely the JAK-STAT3 signalling pathway). 11 Nevertheless, cardiac I/R injury remains as a 'neglected' therapeutic target, although myocardial reperfusion has been greatly improved due to the advances in percutaneous coronary intervention technology and anti-thrombotic therapy. 2, 12 Thus, one of the major focal points of cardiovascular research is to decipher the mechanism underlying I/R injury and identify key signalling pathways and nodal points as potential therapeutic targets for the treatment of such injury and related ischemic cardiomyopathy. b-arrestin 1 (Arrb1) and b-arrestin 2 (Arrb2) are universally expressed and act as negative regulators of G protein signalling via sterically blocking G protein-coupled receptor (GPCR) coupling to G proteins. 13, 14 They also function as scaffold proteins linking activated GPCRs to downstream molecules 15 such as ERK, 16 Src, 17 and Mdm2. 18, 19 More recent studies have demonstrated that some ligands evoke GPCR signal transduction in a G protein-independent, but Arrb-dependent manner, i.e. biased signaling. [20] [21] [22] For instance, Arrb2-dependent biased signalling is indispensable for angiotensin II type 1 receptor (AT1R)-induced cardioprotection against ischemic injury. 23 And several ligands of both the b-adrenergic and urotensin receptors can protect the heart via Arrb-dependent transactivation of the epidermal growth factor receptor. 24, 25 But Arrb1 deficiency attenuates rather than exaggerating the cardiomyocyte death and cardiomyopathy induced by myocardial infarction. 26 Thus, the biological functions and underlying mechanisms of different Arrb family members in the normal and diseased heart are not well understood. The aims of this study were to determine whether and how Arrb1 and Arrb2 are involved in cardiac I/R injury.
Methods
A brief description of the methods is provided below. Detailed description of the methods is available in the Online Data Supplementary material.
Animals
Animals were maintained in the Centre for Experimental Animals, Peking University, Beijing, China, a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care. The animals were randomly allocated to experimental groups. Only male animals were used. No non-inclusion or exclusion parameters were used. We did not blind investigators to treatments, but no subjective assessments were made. Arrb2 knockout mice were gifted by Dr. R. J. Lefkowitz at Duke University Medical Center. 27 Arrb2 transgenic mice were kindly provided by Dr. Gang Pei at Tongji University.
28,29

Rat in vivo I/R injury
Rat in vivo I/R injury was induced as previously described for the detection of the change of cardiac Arrb1 and Arrb2 mRNA and protein levels. 30 Briefly, rats (250-300 g) under anesthesia (40 mg/kg, pentobarbital, i.p.) were ventilated on a Harvard rodent respirator via a tracheostomy and subjected to reversible left anterior descending coronary artery ligation. Myocardial I/R was induced by tightening the ligature for 45 min and then loosening it for 24 h. At the end of reperfusion, the infarcted areas were distinguished from normal tissue and samples of each were collected separately for RNA and protein extraction.
Mouse ex vivo I/R injury using Langendorff perfusion and measurement of cardiac injury
Adult Arrb2-/-mice (or Arrb2 TG mice) and their wt littermates (8-12 weeks) were prepared for ex vivo experiments using a Langendorff perfusion system as described previously. 31 The mice were anaesthetized with pentobarbital (70 mg/kg, i.p.). The constant pressure of Langendorff system was 55 mmHg. Buffers were kept at 37 ± 0.5 C in a heating bath and gassed with 95% O 2 /5% CO 2 (pH 7.35-7.45). Global ischemia was induced by cessation of perfusion for 30 min followed by reperfusion, and myocardial infarct size and lactate dehydrogenase (LDH) release were measured at specific times. To measure the infarct size, each heart was frozen at -80 C for at least 10 min, cut into 5-6 slices, and then incubated in sodium phosphate buffer containing 1% 2,3,5-triphenyl-tetrazolium chloride for 15 min. We used ImageJ software (NIH, Bethesda, MD) to measure the infarct and ventricular areas. Perfusates were collected in parallel to measure LDH release with a spectrophotometric assay kit from Shanghai Gensource Co., Ltd (Cat#: LDH0360).
For TUNEL staining, hearts were fixed overnight in 4% paraformaldehyde (pH 7.4), embedded in paraffin, and cut into sections. TUNEL staining was performed following the manual with the In Situ Cell Death Fluorescein kit from Roche (Cat#: 11684795910).
Echocardiography
Mice were anesthetized with pentobarbital (70 mg/kg, i.p.) and echocardiography was performed as previously described. 30 
Study approval
All procedures involving experimental animals were performed in accordance with protocols approved by the Committee for Animal Research of Peking University, Beijing, China (IMM-XiaoRP-7), and conformed to the Guide for the Care and Use of Laboratory Animals (8th edition The National Academies Press, 2011).
Materials
Antibodies to Arrb2 (Cat#: sc13140), CaV3 (Cat#: sc7665), and HA (Cat#: sc7392) were from Santa Cruz. Antibodies to p-ERK (Cat#: cst 4370), t-ERK (Cat#: cst 4695), p-STAT3 (Cat#: cst 9145), t-STAT3 (Cat#: cst 9139), p-Akt (Cat#: cst 4060 s), t-Akt (Cat#: cst 9272 s), p-GSK3a/b (Cat#: cst 9331 s), t-GSK3b (Cat#: cst 9315 s), PTEN (phosphatase and tensin homolog deleted on chromosome ten) (Cat#: cst 9552), p-PTEN (Cat#: cst 9554), PP2A (Protein Phosphatase 2 A)-B subunit (Cat#: cst 2290), and PP2A-C subunit (Cat#: cst 2259) were from Cell Signalling Technology. Antibody to Arrb1 (Cat#: ab32099-100) was from Abcam, to p85-PI3K (Cat#: ABS233) from Millipore, and to GAPDH from EasyBio (Cat#: BE0023). The Akt inhibitor was from Merck (Cat#: 124005), and the PI3K inhibitor LY294002 from Sigma Aldrich (Cat#: L9908). Unless indicated otherwise, all chemicals were from Sigma.
Statistical analysis
Data are expressed as the mean ± S.E.M. Statistical analyses were performed with GraphPad PRISM version 5.01 (GraphPad Software, Inc.) and the SPSS 18.0 software package (SPSS Inc.). Data sets were tested for normality of distribution with the Kolmogorov-Smirnov test. Data groups (2 groups) with normal distributions were compared using the two-sided unpaired Student's t-test. Comparisons between multiple groups were assessed by one-way ANOVA with Bonferroni post hoc analysis. The P values are presented in the figure legends (*P < 0.05; **P < 0.01). No statistical method was used to predetermine sample size.
Results
Cardiac Arrb2 is upregulated in response to I/R injury
We first investigated the expression of Arrb1 and Arrb2 in the hearts with I/R injury, and found that in the hearts subjected to I/R injury, at both the mRNA and protein levels, Arrb2 expression in the ischemic Figure 1A and B and Supplementary material online, Figure S1A and S2A). Similarly, Arrb2 expression was overtly elevated in cultured rat neonatal cardiomyocytes in response to hypoxia-reoxygenation (H/R), a condition mimicking in vivo I/R injury ( Figure 1C and D and Supplementary material online, Figure S1B and S2B). In addition, oxidative stress with Doxorubicin (Dox) treatment also augmented Arrb2 abundance in the heart (Supplementary material online, Figure S3 ). On the contrary, neither I/R nor H/R injury altered the expression of Arrb1 at the protein level in vivo or in cultured cardiomyocytes ( Figure 1E and F and Supplementary material online, Figure S1 , S2C, and S2D). These results provide multiple lines of evidence that cardiac I/R injury and oxidative stress specifically elevates the expression of Arrb2, but not Arrb1, suggesting that Arrb2 may be the Arrb isoform that is involved in the pathogenesis of I/R injury and related ischemic cardiomyopathy.
Deficiency of Arrb2 alleviates I/Rinduced cardiomyocyte death and myocardial injury
Since I/R selectively upregulates Arrb2, we next evaluated whether Arrb2 is required for the pathogenesis of cardiac I/R injury. It has been reported that Arrbs are distributed in multiple types of cells, including cardiomyocyte, inflammation cells, and adrenal and central sympathetic nerve system, all of which contribute to cardiac ischemic injury. 23, 26, 32 In order to specifically investigate the function of Arrb2 in cardiomyocytes and avoid the complex interaction among different systems, we performed cardiac I/R injury utilizing the ex vivo Langendorff perfused hearts. Arrb2-deficient mice (Arrb2-/-) at 8-12 weeks of age did not show overt cardiac morphology or functional abnormalities compared to wildtype (wt) littermates ( Table 1 Figure 1 Ischemia-reperfusion (I/R) injury elevates Arrb2 but not Arrb1 expression in the heart. A and B, Levels of Arrb2 mRNA (assayed by real-time PCR) (A, n = 6 animals) and protein (assayed by Western blots) (B, n = 8 animals) in normal and infarcted areas of rat heart subjected to I/R injury (45 min ischemia followed by 24 h reperfusion). C and D, Levels of Arrb2 mRNA (assayed by real-time PCR) (C) and protein (assayed by Western blots) (D) in cultured neonatal cardiomyocytes with or without hypoxia-reoxygenation (H/R) injury (9 h hypoxia followed by 3 h reoxygenation). E, Protein levels of Arrb1 (assayed by Western blots) in normal and infarcted areas of rat heart subjected to I/R injury (protocol as in B) (n = 9 animals). F, Protein levels of Arrb1 (assayed by Western blots) in cultured neonatal cardiomyocytes in the presence or absence of H/R injury (protocol as in D). Negative Control (NC) is the heart extracts from Arrb2-/-animals. Values are mean ± S.E.M. of six independent experiments. **P < 0.01, Student's t-test. Figure S6A ), Arrb2-deficient mice were resistant to I/R-induced myocardial damage ( Figure 2) . Specifically, the ratio of infarct area to total left ventricular area (IF/LV) was reduced in Arrb2-/-mice relative to wt counterparts (21.5 ± 3.0% and 36.1 ± 2.2%, respectively) ( Figure 2A ). Cardiomyocyte necrosis (assessed by LDH in the perfusate) and apoptosis (indexed by TUNEL-positive staining) were attenuated by 72.4% and 35.2%, respectively, in Arrb2-/-mice in comparison with wt littermates (Figure 2B and C) . To further evaluate the role of Arrb2 in I/R-induced cardiomyocyte death, we exposed cultured neonatal rat cardiomyocytes to H/R (Supplementary material online, Figure  S6B ). Knockdown of Arrb2 with siRNA (Supplementary material online, Figure S7A ) markedly suppressed the H/R-induced cardiomyocyte death, as evidenced by restored intracellular ATP levels and reduced the LDH concentration in the culture medium ( Figure 2D and E) . In addition, Arrb2 deficiency protected cardiomyocytes against H/R-induced mitochondrial damage, as manifested by abrogating H/R-induced mitochondrial membrane depolarization (assayed by the intensity of JC-1 
Up-regulation of Arrb2 triggers cardiomyopathy and exaggerates I/Rinduced cardiac damage
To further investigate the potential involvement of Arrb2 in the myocardial damage induced by cardiac I/R injury, we investigated transgenic mice overexpressing Arrb2 (Arrb2 TG) (Supplementary material online, Figure S4B , S4C, and S5). 28,29 At 8-12 weeks of age, Arrb2 TG mice displayed depressed cardiac function, as evidenced by decreased ejection fraction and fractional shortening ( Table 2) . Notably, overexpression of Arrb2 markedly exaggerated the I/R-induced myocardial damage. I/Rinduced infarct size was enlarged from 33.8 ± 1.9% to 40.2 ± 1.4% IF/LV in Arrb2 TG hearts compared to the wt littermates ( Figure 3A) . Concurrently, myocyte death was increased, as illustrated by a 2.2-fold augmentation of LDH release and a significant increase in TUNELpositive cells (12.2 ± 0.7% vs. 9.2 ± 0.4%) in Arrb2 TG hearts relative to wt hearts ( Figure 3B and C) . These results reinforce our conclusion that upregulation of Arrb2 is involved in the pathogenesis of I/R injury.
To avoid potential interference of Arrb2 in other types of cells and neurohormonal activation of GPCRs, we used adenoviral gene transfer to overexpress Arrb2 in cultured neonatal rat cardiomyocytes (Supplementary material online, Figure S7B ). Overexpression of Arrb2 was sufficient to trigger cardiomyocyte death in a dose-dependent manner ( Figure 3D and E) . The Arrb2-induced cell death was accompanied by depolarization of the mitochondrial membrane potential ( Figure 3F) . Moreover, adenoviral overexpression of Arrb2 exacerbated H/Rinduced cardiomyocyte death ( Figure 3G and H) . In contrast, overexpression of Arrb1 did not affect cardiomyocyte viability under basal conditions or with H/R-induced oxidative stress (Supplementary material online, Figure S8 ). Thus, upregulation of Arrb2, but not Arrb1, contributes to myocardial I/R injury and cell death, and subsequent ischemic cardiomyopathy and heart failure.
Arrb2 induces cardiomyocyte death by negatively regulating the PI3K-Akt-GSK3b cell survival pathway
We next investigated the mechanism underlying the detrimental effects of Arrb2 on I/R-injured hearts. Two major pathways have been implicated in the protection of the heart against I/R injury, including RISK and SAFE pathways. 10, 11 In hearts from Arrb2-/-mice, under both basal and I/ R conditions, the levels of phosphorylated Akt and its downstream kinase, GSK3b, were significantly higher than those in wt hearts ( Figure 4A , Supplementary material online, Figure S6A ). On the other hand, the phosphorylation levels of both Akt and GSK3b were decreased in Arrb TG mouse hearts with or without I/R injury ( Figure 4B , Supplementary material online, Figure S6A ). In order to further determine the role of Arrb2 in the RISK pathway in cardiomyocytes, we treated the cultured cardiomyocytes with H/R injury. Indeed, consistent with the data from ex vivo perfused hearts, Arrb2 knockdown enhanced, whereas overexpression of Arrb2 suppressed, the phosphorylation of Akt and GSK3b with or without H/R treatment ( Figure 4C and D, Supplementary material online, Figure S6B) . Furthermore, inhibition of the PI3K-Akt-GSK3b pathway with either a PI3K inhibitor (Ly294002) or an Akt inhibitor significantly attenuated the protective effects of Arrb2 knockdown in cultured cardiomyocytes ( Figure 4E and F) . Notably, neither an increase nor a decrease of the Arrb2 level affected the activation of ERK1/2 or STAT3 in cultured cardiomyocytes (Supplementary material online, Figure S9 ), indicating that Arrb2 is specifically involved in the regulation of the PI3K-Akt-GSK3b branch of the RISK pathway. Taken together, we conclude that Arrb2 negatively regulates cardiomyocyte survival by specifically impairing the activation of the PI3K-Akt-GSK3b signalling axis, and that upregulation of Arrb2 contributes to I/R-induced cardiomyocyte death and ischemic cardiomyopathy.
Arrb2 blocks activation of the PI3K-AktGSK3b pathway by preventing the formation of the PI3K-CaV3 survival complex
The protein complex composed of a regulatory subunit of PI3K (p85-PI3K) and caveolin 3 (CaV3) is crucial for the activation of the PI3K-Akt- GSK3b pathway. 31, 33 In cultured cardiomyocytes infected with AdArrb2 and perfused hearts from Arrb2 TG mice, co-immunoprecipitation assays revealed that overexpression of Arrb2 markedly reduced the interaction of p85-PI3K with CaV3 and, more importantly, prevented formation of the p85-PI3K-CaV3 protein complex induced by H/R (or I/ R treatment) ( Figure 5A and B) . On the contrary, decreased Arrb2 levels in both cultured cardiomyocytes and ex vivo hearts, markedly enhanced the physical association of p85-PI3K and CaV3 ( Figure 5C and D) , suggesting that this complex is a direct target of Arrb2 in Arrb2-evoked cardiac cell death signalling. However, overexpression of another Arrb isoform, Arrb1, did not affect the formation of p85-PI3K/CaV3 complex (Supplementary material online, Figure S10 ).
The next question was how Arrb2 impairs the formation of the p85-PI3K/CaV3 complex. Using co-immunoprecipitation assays, we found that hemagglutinin (HA)-tagged Arrb2 interacted with p85-PI3K, but not CaV3, in rat cardiomyocytes ( Figure 6A) . Upon exposure to H/R treatment (9 h hypoxia followed by 30 min reoxygenation), the interaction of Arrb2 with p85-PI3K was clearly enhanced ( Figure 6B ). In addition, using a cell-free system, we found that Arrb2 recombinant protein formed the complex with p85-PI3K protein, indicating that Arrb2 directly interacts with p85-PI3K ( Figure 6C) . Furthermore, overexpression of CaV3 inhibited the interaction between Arrb2 and p85-PI3K under both basal and H/R conditions (Supplementary material online, Figure S11 ). These data indicate that under I/R condition, Arrb2 binds strongly to p85-PI3K and competitively blocks the formation of the p85-PI3K/CaV3 complex, thus disrupting the cardioprotective RISK pathway (Figure 7) . Some other mechanisms, including PP2A 34, 35 and PTEN, 36 have also been demonstrated to be involved in the regulation of PI3K/Akt signalling by Arrbs. We found that the protein levels of neither PP2A B subunit (the targeting subunit) nor the C subunit (the catalytic subunit), which are the major subunits that interacts with Arrb2, 34, 35 are not altered by Arrb2 overexpression or knockout (Figure 8) . Second, in the perfused hearts of wt, Arrb2-/-, and Arrb2 TG mice, although the interaction between PP2A (both B and C subunits) and Akt was abolished by Arrb2 deficiency, and enhanced by Arrb2 overexpression, which is consistent with the previous reports in the brain, 34, 35 the formation of PP2A/Akt complex was not affected by I/R injury (Figure 8 ), indicating that PP2A is unlikely involved in Arrb2-induced inhibition of PI3K/Akt signalling in I/R injured heart. And in cultured cardiomyocyte, neither the phosphorylated nor the total levels of PTEN were changed by Arrb2 overexpression or knockdown (Supplementary material online, Figure S12A and B). Finally, although in cardiomyocytes, PTEN and Arrb2 formed a complex which is consistent with the previous study, 36 this complex was not affected by H/R injury (Supplementary material online, Figure S12C) . Therefore, the inhibition of PI3K-Akt signalling by Arrb2 during cardiac I/R injury is through the impairment of the formation of p85-PI3K/CaV3 complex, but not PP2A or PTEN pathway.
Discussion
A large body of evidence has shown that that Arrb1 and Arrb2 are expressed in multiple organs and tissues including the heart, 37 and both negatively regulate G protein signalling via sterically blocking GPCR coupling to G proteins. Over the past decade, it has been well accepted that Arrbs also act as scaffold proteins linking activated GPCRs to downstream signalling events in a G protein-independent manner, namely biased GPCR signaling. 20, 21 In the heart, ligand-induced activation of certain GPCRs, including the AT1R, 23 b-adrenergic receptor, 24 and urotensin receptor, 25 exert cardiac protective effects via Arrb-dependent, but G protein-independent, biased signalling. Here, we have shown, for the first time, that Arrb2, but not Arrb1, is specifically upregulated by myocardial I/R injury and oxidative stress, and participates in the pathogenesis of cardiomyocyte death and myocardial damage. These findings indicate that the closely related Arrb family members are subjected to distinct regulation and have different biological functions in the heart under normal and disease conditions. The exact mechanism underlying Arrb isoform-specific regulation merits future investigation. Several previous studies have investigated the alterations in the expression level and pathological functions of Arrbs in the settings of myocardial infarction and heart failure, [38] [39] [40] [41] as an important pathogenic factor in cardiac I/R injury. First, overexpression of Arrb2 is sufficient to trigger myocyte death and contractile dysfunction. Second, transgenic overexpression of Arrb2 enhances I/Rinduced myocardial injury. Finally, ablation of Arrb2 protects the heart against I/R-induced cardiac damage. Mechanistically, we have demonstrated that in the isolated perfused hearts and cultured cardiomyocyte, in the absence of ligand stimulation, I/R injury is sufficient to enable Arrb2 to bind to p85-PI3K and competitively suppress the interaction of p85-PI3K with CaV3, thus impairing activation of the PI3K-Akt-GSK3b pro-survival signalling pathway, without altering the ERK1/2 or SAFE pathway. Thus, in addition to its involvement in canonical GPCR signalling as well as biased signalling, Arrb2 mediates GPCR-independent cell death signalling in the heart, thereby contributing to the pathogenesis of I/R injury and the development of ischemic cardiomyopathy. It is noteworthy that this newly identified effect of Arrb2 is in opposition to the previous notion that Arrb2 is required for the cardioprotection induced by biased ligand 23 and the activation of some other receptors. 24, 25 This suggests that the receptor-dependent and -independent Arrb2 signalling pathways exert different, or even opposite cellular functions. Previous studies have reported that biased GPCR ligands can induce G protein-independent interactions of Arrb2 with ERK1/2 16 and CaMKII. 42 It is reasonable to assume that different upstream stimuli may trigger distinct Arrb2 conformational states, thus affecting pathways that are either beneficial or detrimental to the heart, depending on particular proteins that interact with specific Arrb2 conformations. In addition, the distinctly different functions of Arrb1 and Arrb2 might be also attributed to their different subcellular distributions and distinct interacting proteins. Nevertheless, these possibilities require future investigation. Cardiac I/R injury causes oxidative stress in cardiomyocytes 6 , and It has been shown increased production of reactive oxidative species (ROS) activates receptor tyrosine kinases (RTKs) through the oxidation and subsequent inhibition of the protein phosphatases (e.g. PTP1B, SHP-2, and TC45), which are negative regulators of RTKs. 43, 44 The activated RTKs will promote the activation of PI3K cascade. 45, 46 Our previous studies have demonstrated that the p85-PI3K/CaV3 complex is essential for the activation of PI3K-Akt signaling. 31, 33 And here, we provided evidence that increased Arrb2 abundance inhibits the formation of p85-PI3K/CaV3 complex and impairs cardiomyocyte viability in the absence of GPCR stimulation in cultured cardiomyocytes. Thus, the present findings reveal a novel function of Arrb2 in the regulation of cardiomyocyte injury, which is mediated by a GPCR-independent mechanism. Besides cardiomyocytes, Arrb2 is universally distributed in other cell types, including inflammation cells and sympathetic nerve system, all of which also contribute to cardiac I/R damage. 26, 32 In the previous studies utilizing in vivo cardiac injury model, 22, 23, 26, 32 it is impossible to decipher the function of Arrbs in different cell types. With the ex vivo perfused hearts and cultured cardiomyocytes, we are able to identify that Arrb2 promotes cardiomyocyte death via preventing the formation of p85-PI3K/CaV3 survival complex and the subsequent activation of PI3K-AktGSK3b pro-survival signalling pathway. Since CaV3 is strictly located in cardiac and skeletal muscle cells, this Arrb2-related signalling and cell death-inducing effect may be striated muscle specific. It merits future investigation to determine whether the GPCR-independent, Arrb2-mediated cell death signalling is applicable to other cell types. In a previous report, Arrb1, but not Arrb2, is the key mediator of cardiac injury and heart failure induced by myocardial infarction. 26 Here in our study, we found that upregulation of Arrb2, but not Arrb1, is responsible for I/R-induced cardiomyocyte death. It has been shown that myocardial infarction (with permanent ligation of the coronary artery) differs from I/R (with transient ligation of the coronary artery followed by reperfusion) in pathophysiology, signal transduction, and therapeutic strategy. 2, 12, 47 Although both ischemia (MI) and subsequent I/R injury represent equally important but distinct therapeutic targets, until recently, I/R injury was a neglected therapeutic target for cardioprotection 2 . The current finding that Arrb2, instead of Arrb1, plays an important role in the mediation of cardiac I/R injury, shedding new light on our understanding of the pathogenic and therapeutic significance of I/R in myocardial injury and heart failure.
In summary, there are three major findings in the present study. First, we have shown that Arrb2 in the hearts is upregulated in response to cardiac oxidative stress and I/R injury in the absence of alterations in the expression of Arrb1. Second, upregulation of Arrb2 triggers cardiomyocyte death and exaggerates oxidative stress-induced cardiac damage and cardiomyopathy, whereas its downregulation protects the heart against I/R-induced myocardial injury. Third, Arrb2 binds to p85-PI3K and subsequently prevents its interaction with CaV3, thus impairing activation of the PI3K-Akt-GSK3b pro-survival pathway. These findings not only reveal a previously unappreciated novel function of Arrb2 in blocking I/ R-induced activation of the pro-survival RISK pathway, but also mark Arrb2 as a potentially important therapeutic target for cardiomyopathy caused by various etiologies. 
Supplementary material
Supplementary material is available at Cardiovascular Research online. Figure 8 PP2A/Arrb2/Akt complex is not involved in cardiac I/R injury. A, Typical Western blots and averaged data of co-immunoprecipitation of PP2A (both B and C subunits) and AKT in hearts from wt and Arrb2-/-mice under basal condition and after I/R injury (n = 6 animals). B, Typical Western blots and averaged data of co-immunoprecipitation of PP2A (both B and C subunits) and AKT in hearts from wt and Arrb2 TG mice under basal conditions and after I/R injury (n = 6 animals). Values are mean ± S.E.M. of six independent experiments. *P < 0.05, **P < 0.01, One-way ANOVA. 
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